Rare Oncology CRO
Support for rare oncology beyond standard oncology execution
Worldwide helps sponsors de-risk and deliver rare oncology studies with proven expertise in biomarker-defined populations, complex logistics, patient-centric strategies, and the urgency of bringing new treatment options to patients with uncommon cancers.
Tell us about your study
We’ll connect you with the right oncology clinical
development team.
Your Rare Oncology Trial Challenges
Why Rare Oncology Development Needs Specialized Support
Rare oncology studies bring a level of complexity that standard oncology models are not designed to address. Patient populations may be ultra-small, biomarker-defined, geographically dispersed, or tied to a limited number of specialty centers. In aggressive cancers, delays can quickly compromise treatment windows, enrollment, and study viability. Across these programs, sponsors need support that can connect scientific complexity, patient burden, and operational execution from the start. More than 30% of Worldwide’s oncology studies awarded are in rare cancers, reflecting how often the team is helping sponsors navigate these realities.
Global Reach Must Match Patient Reality
Rare oncology enrollment success depends on more than broad geographic coverage. Worldwide helps sponsors reach the right patients through footprint planning informed by disease epidemiology, referral patterns, and specialty-site access.
Aggressive Cancers Leave Less Room for Delay
In fast-moving cancers, speed is critical because patients need immediate treatment, and delays can quickly impact enrollment and study momentum. Worldwide helps sponsors address feasibility and execution risks early, minimizing later disruption.
Biomarker-Defined Populations Add Complexity Early
Rare oncology studies are increasingly shaped by tumor biology, biomarker stratification, and evolving modalities that further limit already small patient populations. Worldwide helps sponsors plan for this complexity earlier.
Patient Burden Can Affect Participation
Complex treatment journeys can make participation challenging for patients and caregivers. Worldwide helps sponsors reduce friction through practical feasibility planning and dedicated support for patients, samples, and IP logistics.
Partnership & Approach
A Partner for Rare Oncology Trial Complexity
Rare oncology requires sponsors to address scientific, operational, and patient-access challenges simultaneously. Worldwide helps teams assess feasibility earlier, mitigate execution risks sooner, and navigate logistics and stakeholder coordination confidently, so rare oncology challenges are less likely to become avoidable delays later.
Deep Rare Oncology Expertise
Rare Oncology Studies in the Past 5 years
Patients Enrolled
Unique Sites
Why Worldwide
What Makes Worldwide the Right Rare Oncology Trial Fit?
Rare oncology can demand more from a CRO than standard oncology execution alone. Worldwide brings oncology-specific rigor, rare-disease logistics, and practical support for studies shaped by complexity, urgency, and limited patient access.
Rigor Plus Logistics
Rare oncology brings a level of complexity that requires more than oncology experience alone. Worldwide combines oncology-specific scientific rigor with the specialized logistical support often required in rare disease settings.
Ready for Rare Programs
Rare oncology studies involve low-prevalence populations, limited precedent, and non-routine operational demands. Worldwide supports sponsors with an approach purpose-built for that level of complexity.
Patient Feasibility in Focus
Complex treatment journeys can create real barriers to patient participation. Worldwide helps sponsors evaluate study feasibility in real-world terms for patients and caregivers, not solely through protocol requirements.
Patient Community Connections
Rare oncology studies often depend on collaboration with advocacy groups, consortia, or specialized external partners. Worldwide understands how these relationships support effective study planning and execution.
Support When Indications Are New
In rare oncology studies where there may be little precedent to follow, Worldwide helps sponsors move forward with confidence by applying relevant insights early to minimize trial-and-error as programs advance.
Services & Capabilities
Comprehensive Oncology CRO Services
- Protocol Design and Clinical Development Planning
- Regulatory Consulting and Global Submissions
- Global Project Management
- Feasibility Analysis and Site Selection Strategy
- Site Initiation and Study Start-up
- Patient Enrollment
- Dose Escalation, Optimization and Cohort Management
- Site Monitoring and Management
- Data Management
- Clinical Data Analytics and Review
- Clinical Science
- Biostatistics
- Medical Monitoring
- Safety / Pharmacovigilance
- Medical Writing
Rare Oncology Strategy
Worldwide partners with sponsors to plan and execute rare oncology studies, addressing operational complexity, feasibility considerations, and the realities of developing therapies for uncommon cancers.
Biomarker-Driven Support
For studies shaped by biomarkers or precision-medicine approaches, Worldwide helps sponsors align execution decisions with the demands of increasingly narrow patient populations.
Specialized Population Support
Rare oncology studies may involve pediatric, geriatric, or other specialized populations that add complexity. Worldwide helps sponsors incorporate these considerations into practical study planning and execution.
Specialized Site Readiness
Successful rare oncology studies often depend on access to the right academic centers, referral pathways, and specialty sites. Worldwide helps sponsors anticipate and plan for these access needs early.
What Our Clients Say
“That’s one of the things, which we heard about Worldwide Clinical Trials from other people in the industry, also. Their experience in rare disease category. And also, rare places where they can do the work.”
Senior Director, Clinical Operations – Late Phase | Mid-sized Biopharma (North America)
FAQ & Insights
What Sponsors Need to Know
Worldwide defines rare oncology as studies where the scientific and safety demands of oncology intersect with the operational realities of rare disease, including smaller, harder-to-find patient populations, more complex logistics, and greater execution uncertainty than standard oncology trials.
These studies frequently demand more than standard oncology execution. Patient identification can be difficult, logistics more involved, and trial feasibility may depend on specialized sites, referral pathways, caregiver burden, and early operational decisions.
Worldwide’s rare oncology approach is built specifically for the overlap of oncology rigor and rare-disease complexity. This allows sponsors to address both the scientific demands of oncology and the operational challenges that can affect startup, enrollment, and study conduct.
Yes. Rare oncology studies are often shaped by biomarkers or precision-medicine approaches that further narrow already small populations. Worldwide helps sponsors plan and execute these studies with approaches suited to that level of specificity and operational sensitivity.
When appropriate for the program, Worldwide supports studies that involve advocacy groups, consortia, or specialized external stakeholder groups. The team understands how these relationships can support study planning, patient access, and execution.
In rare oncology, patient burden can directly affect participation and retention. Worldwide helps sponsors evaluate study demands from a practical perspective, so execution decisions better support patients and caregivers across complex treatment journeys.
Rare oncology studies may face risks around patient access, logistics, specialty-site readiness, external coordination, and execution timing. Worldwide helps sponsors surface and address those issues earlier, reducing the likelihood of avoidable study delays later.
Yes. Rare oncology support is not limited to having prior experience in that exact indication, whether it’s new to Worldwide or to the industry as a whole. Worldwide applies relevant oncology and rare disease lessons to new or uncommon indications, helping sponsors progress novel science into the clinic and to patients in need.
Oncology Expertise
Looking for Other Oncology Specializations?
See what Worldwide Clinical Trials can do for you.
Your study has unique goals, risks, and decisions ahead. Tell us a little about your needs, and our team will connect you with the right Worldwide experts to discuss how our scientific, medical, and operational support can help move your program forward with confidence.
